ABC ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
256筋型糖原病1
265脂肪萎縮症1

256. 筋型糖原病


臨床試験数 : 180 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02938520
(ClinicalTrials.gov)
October 27, 201615/9/2016Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsA Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult ParticipantsHIV Infections;Glycogen Storage Disease Type IIDrug: Cabotegravir (CAB) tablet;Drug: Rilpivirine (RPV) tablet;Drug: Cabotegravir - Injectable Suspension (CAB LA);Drug: Rilpivirine - Injectable Suspension (RPV LA);Drug: ABC/DTG/3TC STR - Tablet;Drug: DTG TabletViiV HealthcareJanssen Pharmaceuticals;GlaxoSmithKlineActive, not recruiting18 YearsN/AAll631Phase 3United States;Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;South Africa;Spain;United Kingdom

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00865007
(ClinicalTrials.gov)
December 200818/3/2009Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With LipoatrophyA Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/RitonavirHIV Infection;Lipodystrophy;HIV InfectionsDrug: Monotherapy (Lopinavir/ritonavir);Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TCFundacion SEIMC-GESIDAAbbottCompleted18 YearsN/ABoth88Phase 4Spain